Janssen Biotech licenses ImmuNext's VISTA therapeutics; ImmuNext regains rights to CI8993
Johnson & Johnson’s Janssen Biotech Inc. has licensed exclusive global development and commercialization rights to ImmuNext Inc.’s (oncology and immunology therapeutics) preclinical cancer immunotherapies, which antagonize the VISTA (V-region immunoglobulin-containing suppressor of T-cell activation) signaling pathway.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com